PropertyValue
?:abstract
  • Drugmaker Pfizer has begun Phase I clinical tests of PF-07304814, a small molecule that could be used to fight SARS-CoV-2, the virus that causes COVID-19 The compound targets the , an enzyme that coronaviruses like SARS-CoV-2 use to assemble themselves and multiply Mucking up that bit of self-replication machinery can shut down the viruses If approved, PF-07304814 would be the first antiviral drug to target this protein “We believe this potential first-in-class protease inhibitor may give us the best opportunity to show meaningful antiviral activity to help treat COVID-19 patients,” Mikael Dolsten, Pfizer’s chief scientific officer, said during a video presentation to investors on Sept 15 PF-07304814 contains a phosphate group that makes the compound soluble and gets cleaved by alkaline phosphatase enzymes in tissue, releasing the active antiviral PF-00835231 Pfizer chemists first discovered that active compound, which was designed to target the 3CL protease of SARS-CoV, during the 2002–3 [ ]
is ?:annotates of
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Pfizer tests COVID-19 antiviral
?:type
?:who_covidence_id
  • #801504
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/0ixp1n47>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/0ixp1n47>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all